The Food and Drug Administration recently approved a new antibiotic into the arsenal for treating serious acute bacterial skin and skin structure infections (ABSSSI).
Its called delafloxacin and goes by the trade name, Baxdela and its manufactured by Melinta Therapeutics.
Assistant Professor of Medicine, David Geffen School of Medicine at UCLA, James McKinnell, M.D. joined me to discuss the importance of this approval.
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Stitcher | RSS
Related:
- MRSA, C. diff and other healthcare-associated infections
- France reports nearly 800 hepatitis A cases in first five months of 2017
- Hepatitis C: California reports increase in young adults
- Antibiotics effective for treatment of simple abscesses: Study
- RSV discovery provides potential target for vaccines, treatments
- Louisiana: Naegleria fowleri amoeba found in drinking water in Ouachita Parish
- Memphis: Legionnaires’ disease outbreak reported at Graceland
- Cyclospora outbreak reported in Ontario, British Columbia
- Lyme: Q & A with Paul Auwaerter, MD
- Polio: Additional cases reported in Syria
- Infection control breach prompts notification letters to Covenant Health patients
- New antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS
- Cholera epidemic: 40,000 new cases reported in Yemen during past week
Image/NIAID
